BioXcel said the Phase 3 trial is designed to evaluate the safety of BXCL501. The trial's topline-data results, which are expected in the second half of 2025, are intended to support a potential ...

This condition might interfere with treatments with oral drugs. Unlike intravenous injections, sublingual tablets can also be used outside of the hospital setting, offering the potential of use at ...

ED treatment from Roman that does just that. It combiness FDA-approved active ingredients to give individuals the fast-acting ...

GLP-1 medications have become a popular tool for weight loss and metabolic health, but with their rise in popularity, ...

Tonix stock, on last look, is up 24.4% to $13.57 as of 12:58 p.m. GMT-5 on Thursday. Two double-blind, placebo-controlled ...

The U.S. Food and Drug Administration has expanded its indication of ALK's Odactra, a house dust mite allergen tablet, for ...

The US Food and Drug Administration (FDA) has expanded the use of Odactra to include children aged 5 to 11 years. Previously, ...

The global allergy immunotherapy market is poised for significant growth, projected to expand from USD 1.94 billion in 2025 ...

Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is completeTest results support the ...

New product expected to set a new standard for potency and performance in the estimated $20 billon pre-workout market ...

Aspire Biopharma (ASBP) announced that Glatt Air Techniques has undertaken FDA-required testing of the Company’s high-dose sublingual aspirin ...